A share price of Harmony Biosciences Holdings Inc [HRMY] is currently trading at $34.84, up 0.37%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HRMY shares have gain 6.38% over the last week, with a monthly amount glided 4.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On February 11, 2025, Deutsche Bank initiated with a Buy rating and assigned a price target of $55 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $75 on December 17, 2024. UBS started tracking with a Buy rating for this stock on September 10, 2024, and assigned it a price target of $56. In a note dated June 21, 2024, Citigroup initiated an Buy rating and provided a target price of $48 on this stock.
Harmony Biosciences Holdings Inc experienced fluctuations in its stock price throughout the past year between $26.47 and $41.61. Currently, Wall Street analysts expect the stock to reach $40.5 within the next 12 months. Harmony Biosciences Holdings Inc [NASDAQ: HRMY] shares were valued at $34.84 at the most recent close of the market. An investor can expect a potential return of 16.25% based on the average HRMY price forecast.
Analyzing the HRMY fundamentals
Trailing Twelve Months sales for Harmony Biosciences Holdings Inc [NASDAQ:HRMY] were 744.85M which represents 19.48% growth. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.21%. To continue investigating profitability, this company’s Return on Assets is posted at 0.14, Equity is 0.24 and Total Capital is 0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.33 points at the first support level, and at 33.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.16, and for the 2nd resistance point, it is at 35.47.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Harmony Biosciences Holdings Inc [NASDAQ:HRMY] is 3.67. As well, the Quick Ratio is 3.63, while the Cash Ratio is 2.79. Considering the valuation of this stock, the price to sales ratio is 2.69, the price to book ratio is 2.78 and price to earnings (TTM) ratio is 13.28.
Transactions by insiders
Recent insider trading involved JEFFREY G DIERKS, Former Officer, that happened on Jun 10 ’25 when 5615.0 shares were purchased. Former Officer, JEFFREY G DIERKS completed a deal on May 19 ’25 to buy 9844.0 shares. Meanwhile, Former Officer JEFFREY G DIERKS bought 2292.0 shares on May 16 ’25.
